Chemotherapy strategies for metastatic PDAC

Описание: This video, developed by Prof. Efrat Dotan and Prof. Shubham Pant, reviews the combination chemotherapy strategies available as 1st and 2nd line treatments for metastatic pancreatic ductal adenocarcinoma (PDAC) that have led to improved survival rates for these patients. 
Topics covered in this video include: 
Key trial data for the combination chemotherapy strategies used as 1st and 2nd line treatments  
Cause of toxicities and strategies that can be used to improve tolerability 
Management of vulnerable patients 
Maintenance therapy 
Download the slides and summary flashcard and access the accredited e-learning here: https://cor2ed.com/gi-connect/program...

Key clinical takeaways:  
Pancreatic ductal adenocarcinoma (PDAC) is usually diagnosed at an advanced, incurable stage and has an extremely poor prognosis 
Systemic chemotherapy is the standard treatment for metastatic PDAC (mPDAC) but molecularly targeted treatments and immunotherapies may have a role for specific patients 
Treatment selection depends on several factors, including patients' performance status and co-morbidities. These should be considered alongside the efficacy and safety profiles of the different chemotherapy regimens 
Treatment strategies can be implemented to manage toxicities associated with the different chemotherapy regimens to enable a patient to stay on treatment for optimal efficacy

Follow us on social media:

LinkedIn:   / giconnect  

X: https://x.com/giconnectInfo

This content is intended for healthcare professionals only.

The medical experts in this video are expressing their own views and not those of COR2ED, Supporters or their institution. This video is supported by an Independent Education Grant from Ipsen USA

This video was developed by cor2ed.com

Published in December 2024